Cart
sales@molnova.com
MSX-130
CAS No. 4051-59-6
MSX-130( MSX-130 | MSX 130 | MSX130 )
Catalog No. M17502 CAS No. 4051-59-6
MSX-130 is CXCR4 Antagonist.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 33 | In Stock |
|
| 5MG | 51 | In Stock |
|
| 10MG | 87 | In Stock |
|
| 25MG | 188 | In Stock |
|
| 50MG | 305 | In Stock |
|
| 100MG | 477 | In Stock |
|
| 200MG | 677 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMSX-130
-
NoteResearch use only, not for human use.
-
Brief DescriptionMSX-130 is CXCR4 Antagonist.
-
DescriptionMSX-130 is CXCR4 Antagonist.
-
In VitroThe C-X-C chemokine receptor-4 (CXCR4) is a seven trans-membrane G-protein coupled receptor (GPCR) classified as a member of the family I GPCR or rhodopsin-like GPCR family. CXCR4 plays an important role in cancer metastasis, regulation of stem cell trafficking, and neovascularization.
-
In Vivo——
-
SynonymsMSX-130 | MSX 130 | MSX130
-
PathwayAutophagy
-
TargetCXCR
-
RecptorCXCR4
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number4051-59-6
-
Formula Weight514
-
Molecular FormulaC36H26N4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 2 mg/mL (3.89 mM)
-
SMILESc1(ccc(cc1)c1nc(c([nH]1)c1ccccc1)c1ccccc1)c1[nH]c(c(n1)c1ccccc1)c1ccccc1
-
Chemical Name2,2'-(1,4-Phenylene)bis[4,5-diphenyl-1H-imidazole]
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Weiqiang Zhan, et al. Discovery of Small Molecule CXCR4 Antagonists. J. Med. Chem., 2007, 50 (23), pp 5655–5664.
molnova catalog
related products
-
ALX 40-4C
ALX40-4C is a small peptide inhibitor of the chemokine receptor CXCR4 that can inhibit X4 strains of HIV-1.
-
CHIR98014
CHIR 98014 is a potent GSK-3α/β inhibitor with IC50 of 0.65 nM/0.58 nM in cell-free assays, with the ability to distinguish GSK-3 from its closest homologs Cdc2 and ERK2.
-
Ulocuplumab
Ulocuplumab (BMS-936564) is a fully human anti-CXCR4 IgG4 antibody.Ulocplumab exhibits antitumor activity in acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL), and multiple myeloma transplantation models.
